Danielle Magness-Wellmann, DO
Psychiatry · Mankato, MNNPI 1679729164
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $166,590 of the $232,459 with a category attached, or 71.7%. 24 manufacturers reported payments, led by AbbVie at 27.7% of the total. Among psychiatry clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 446 payments — averaging $521.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$64K
- Axsome Therapeutics, Inc.$56K
- Otsuka America Pharmaceutical, Inc.$45K
- Teva Pharmaceuticals USA, Inc.$29K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$22K
- Tris Pharma Inc$7K
- plus $9K from 18 others
Across 9 payments — averaging $8411.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$76K
What the payments were for
- Consulting fees$41,15118%
- Speaking & faculty fees$166,59072%
- Travel & lodging$19,6558%
- Food & beverage$5,0312%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 108 | $64,420 |
| Axsome Therapeutics, Inc. | 77 | $56,457 |
| Otsuka America Pharmaceutical, Inc. | 86 | $44,975 |
| Teva Pharmaceuticals USA, Inc. | 53 | $28,933 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $21,725 |
| Tris Pharma Inc | 13 | $7,195 |
| Biogen | 4 | $6,684 |
| Sunovion Pharmaceuticals Inc. | 12 | $1,187 |
| Supernus Pharmaceuticals, Inc. | 6 | $120 |
| Acadia Pharmaceuticals Inc | 7 | $112 |
| Corium, LLC | 12 | $110 |
| Ironshore Pharmaceuticals Inc. | 7 | $97 |
| Harmony Biosciences LLC | 4 | $96 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Alkermes, Inc. | 5 | $63 |
| Almatica Pharma LLC | 3 | $40 |
| Sage Therapeutics, LLC | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Eisai Inc. | 2 | $30 |
| Indivior Inc. | 1 | $20 |
| Novo Nordisk | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$63,120
- Auvelity$54,986
- REXULTI$43,788
- Austedo XR$24,499
- CAPLYTA$21,034
- Dyanavel XR$7,105
- Quillivant$7,105
- Quillichew ER$7,105
- Zurzuvae$6,684
- AUSTEDO$3,679
- LATUDA$1,120
How this compares
$232,459 in reported general payments places this provider in the 95th percentile of 552 psychiatry providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 47 | $494,690 |
| VraylarCariprazine Hcl | 140 | $243,215 |
| RexultiBrexpiprazole | 168 | $222,415 |
| IngrezzaValbenazine Tosylate | 16 | $133,122 |
| Invega SustennaPaliperidone Palmitate | 21 | $67,440 |
| Abilify MaintenaAripiprazole | 20 | $48,610 |
| AuvelityDextromethorphan Hbr/Bupropion | 36 | $44,615 |
| VyvanseLisdexamfetamine Dimesylate | 99 | $38,364 |
| TrintellixVortioxetine Hydrobromide | 48 | $32,383 |
| Lisdexamfetamine Dimesylate | 123 | $28,826 |
| Vilazodone Hcl | 186 | $19,643 |
| Aripiprazole | 242 | $17,577 |
| Lurasidone Hcl | 46 | $13,941 |
| BelsomraSuvorexant | 30 | $13,582 |
| FetzimaLevomilnacipran Hcl | 16 | $13,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $28,933 | $494,69047 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $44,975 | $271,025188 claims |
| AbbVieVraylar, Fetzima | $64,420 | $256,625156 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $14 | $133,12216 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $33 | $70,747147 claims |
| Johnson & JohnsonInvega Sustenna | $13 | $67,44021 claims |
| Axsome Therapeutics, Inc.Auvelity | $56,457 | $44,61536 claims |
| Eisai Inc.Dayvigo | $30 | $10,88422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 552 psychiatry providers in Minnesota.
Other psychiatry in Mankato
- Michael FarnsworthMankato$548K
- Edward SathoffMankato$1K
- Robert OlsonMankato$1K
- Veronica RadiganMankato$496
- Michael MoellerMankato$483
- Sujit VarmaEdina$581K
- Craig VineSt Paul$136K
- Thomas WinegardenChanhassen$55K
- John LuehrMinnetonka$41K
- Walter RushSaint Paul$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.